List of Excipients in Branded Drug ARIPIPRAZOLE

« Back to Dashboard

Generic Drugs Containing ARIPIPRAZOLE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	FD&C BLUE NO. 2
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	ISOPROPYL ALCOHOL
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	LACTOSE MONOHYDRATE
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	MAGNESIUM STEARATE
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	POVIDONE
NCS HealthCare of KY Inc dba Vangard Labs	aripiprazole	0615-8259	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in ARIPIPRAZOLE?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
1	ALUMINUM OXIDE
13	ASPARTAME
2	BENZYL ALCOHOL
2	BUTYLATED HYDROXYANISOLE
9	CALCIUM STEARATE
176	CELLULOSE, MICROCRYSTALLINE

Aripiprazole Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Aripiprazole has a mature oral generic market and a growing long-acting injectable market. The main excipient opportunities are in taste masking, orally disintegrating tablets, low-cost bioequivalent formulations, sterile depot suspensions, prefilled delivery systems, and differentiated long-acting products based on aripiprazole lauroxil or aripiprazole monohydrate. The commercial value is higher in injectable delivery than in standard immediate-release tablets because formulation performance, manufacturing controls, device compatibility, and clinical substitution barriers are more difficult to replicate.

What dosage forms and excipients are used in aripiprazole products?

Aripiprazole is marketed as immediate-release tablets, orally disintegrating tablets, oral solution, and long-acting injectable products. Aripiprazole lauroxil is a prodrug used in the Aristada and Aristada Initio products.

Product	Active ingredient or prodrug	Dosage form	Key excipient strategy
Abilify tablets	Aripiprazole	Immediate-release tablet	Conventional lactose, starch, cellulose, hydroxypropyl cellulose, magnesium stearate and sodium lauryl sulfate system
Generic aripiprazole tablets	Aripiprazole	Immediate-release tablet	Low-cost direct compression or wet-granulation platforms with broad excipient substitution options
Abilify Discmelt	Aripiprazole	Orally disintegrating tablet	Mannitol, crospovidone, microcrystalline cellulose, sweetener, flavor and acidulant system
Abilify oral solution	Aripiprazole	Oral solution	Solubilization, preservation, pH control and palatability system
Abilify Maintena	Aripiprazole monohydrate	Extended-release injectable suspension	Sterile crystalline drug particles, suspending agents, tonicity agents and phosphate buffering
Asimtufii	Aripiprazole monohydrate	Two-month extended-release injectable suspension	High-drug-load sterile suspension with similar depot excipient architecture
Aristada	Aripiprazole lauroxil	Extended-release injectable suspension	Prodrug particle engineering, suspension stabilization and sterile prefilled delivery
Aristada Initio	Aripiprazole lauroxil	One-time initiation injection	Higher-release formulation designed to establish exposure rapidly

The FDA label for Abilify tablets identifies inactive ingredients that include corn starch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate.[1] The orally disintegrating formulation uses a different platform centered on mannitol, crospovidone, microcrystalline cellulose, sweetening agents and flavor-related excipients.[2]

Maintena and Asimtufii use a sterile powder-for-suspension presentation. Their excipient systems include carboxymethylcellulose sodium, mannitol and phosphate-buffered components.[3,4] These excipients support suspension formation, osmolality and injectable handling but do not eliminate the need for tight control of particle size, polymorphic form, sedimentation, redispersibility and injection force.

Which excipients create the strongest commercial opportunities?

The most attractive opportunities are excipients that solve a specific formulation or manufacturing problem rather than simple replacement of commodity fillers.

Taste-masking and orally disintegrating tablets

Orally disintegrating aripiprazole products face three technical issues:

1. The drug has limited aqueous solubility.
2. Rapid disintegration can increase bitterness exposure.
3. The final tablet must retain sufficient mechanical strength for packaging and handling.

Commercially relevant excipient technologies include:

• Coated or embedded drug particles.
• Ion-exchange resin complexes.
• Cyclodextrin complexes.
• Lipid or polymeric taste-masking systems.
• High-efficiency superdisintegrants.
• Co-processed mannitol-cellulose platforms.
• Low-moisture granulation systems.
• Flavor and sweetener systems compatible with psychiatric medicines.

Mannitol remains attractive because it provides a cooling mouthfeel, low hygroscopicity and acceptable tablet disintegration. Crospovidone, croscarmellose sodium and sodium starch glycolate can be evaluated for disintegration, although their performance depends on drug loading and compression force.

A differentiated generic could target patients with swallowing difficulty, institutional care settings, or adherence problems. The principal constraint is regulatory equivalence. A formulation with a materially different excipient system may require comparative bioavailability work and, in some cases, additional safety justification if the excipient is novel or used at a high exposure.

Oral solution and pediatric-oriented products

Aripiprazole oral solution creates opportunities in:

• Preservative systems.
• Sugar-free formulations.
• Alcohol-free formulations.
• Improved flavor masking.
• Unit-dose packaging.
• Ready-to-use oral syringes.
• Lower-volume concentrated solutions.
• Excipient systems suitable for patients with metabolic or dietary restrictions.

The FDA-approved oral solution contains excipients including edetate disodium, fructose, glycerin, methylparaben, propylene glycol, purified water and pH-adjusting components.[5] A reformulated product could compete through improved palatability, reduced sugar, lower propylene glycol exposure or better package usability.

The principal technical challenge is maintaining chemical stability while controlling precipitation and preservative performance. A solution with lower cosolvent content may require pH optimization, complexation or a different solubilization strategy.

Long-acting injectable suspensions

Long-acting injectable aripiprazole products offer the highest-value excipient opportunity. The formulation must balance:

• Drug concentration.
• Particle size distribution.
• Syringeability.
• Injection-site tolerability.
• Sedimentation rate.
• Redispersibility.
• Release duration.
• Sterility assurance.
• Container closure compatibility.

For aripiprazole monohydrate products, the drug itself is the main depot-forming component. Excipients control the injectable suspension environment. Carboxymethylcellulose sodium can increase viscosity and reduce sedimentation. Mannitol can support the dried powder matrix and contribute to tonicity after reconstitution. Phosphate components support pH control.

The commercial opportunity is greatest in excipients that permit higher drug loading or lower injection volume. A formulation that reduces reconstitution time, decreases injection force, or improves suspension uniformity can have practical value even without changing the active ingredient.

Potential supplier opportunities include:

• Low-bioburden injectable-grade suspending polymers.
• Narrow-specification carboxymethylcellulose.
• Sterile or low-endotoxin mannitol.
• Optimized phosphate buffer systems.
• Polymer coatings for controlled particle wetting.
• Ready-to-use suspension vehicles.
• Prefilled syringe-compatible formulations.
• Excipient systems that reduce needle clogging.

How does aripiprazole lauroxil change the excipient strategy?

Aripiprazole lauroxil is a covalent prodrug of aripiprazole used in Aristada. It is designed to convert to aripiprazole after administration, providing prolonged exposure.[6] The formulation strategy therefore differs from the aripiprazole monohydrate depot products.

The principal formulation variables are:

• Prodrug particle size.
• Surface area and morphology.
• Hydrolysis rate.
• Suspension viscosity.
• Wetting behavior.
• Release from the injection site.
• Prefilled syringe performance.

Aristada uses a sterile injectable suspension with excipients including polysorbate 20, sodium chloride, phosphate components, sodium hydroxide and water for injection.[7] Polysorbate 20 supports wetting and suspension stability, while sodium chloride and phosphate components help control the injectable vehicle.

The excipient opportunity is narrower than in a conventional tablet because the release profile is closely linked to the prodrug particle and formulation architecture. A change in surfactant concentration or polymer content can alter release kinetics, local tolerability and exposure. That raises development risk but also increases switching barriers for competitors.

What formulation patents protect aripiprazole products?

Aripiprazole patent protection differs sharply by product class.

Product category	Patent and exclusivity position	Competitive implication
Immediate-release tablets	Core compound protection has expired; generic tablets are widely approved	Commodity competition and price erosion
Orally disintegrating tablets	Product-specific formulation and method patents may have provided historical protection; current exposure depends on listed patents and claims	Moderate opportunity for differentiated ODT products
Oral solution	Product-specific formulation claims may affect development strategy	Opportunity depends on formulation freedom to operate
Abilify Maintena	Long-acting injectable formulation and manufacturing claims are more important than the expired compound patent	Higher barrier to substitutable products
Asimtufii	Later-generation two-month depot product with product-specific regulatory and patent considerations	Longer commercial protection than immediate-release aripiprazole
Aristada	Prodrug, particle, depot and administration patents may be relevant	Stronger technical barrier than standard aripiprazole
Aristada Initio	Initiation regimen and formulation claims may affect competing launch strategies	Potentially significant combination of formulation and method-of-use protection

The Orange Book lists patents and regulatory exclusivity for approved drug products, but listings can change over time and must be reviewed by product and application number.[8] A commercial assessment should distinguish:

• Active ingredient patents.
• Formulation patents.
• Particle-size or polymorph patents.
• Manufacturing-process patents.
• Device patents.
• Method-of-use patents.
• Administration-regimen patents.
• Patent-term extensions and pediatric exclusivity.

A tablet manufacturer generally faces limited freedom-to-operate risk once core compound and listed product patents have expired. A long-acting injectable competitor faces a more complex patent landscape because a noninfringing product must reproduce the desired pharmacokinetic profile without copying protected formulation, particle or administration claims.

When did aripiprazole lose generic exclusivity?

Immediate-release aripiprazole tablets are no longer protected by meaningful market exclusivity in the United States. FDA-approved generic tablets entered the market after expiration of the principal Abilify compound and product protection period.[9]

The long-acting products have different timelines. Approval of Abilify Maintena in 2013, Aristada in 2015, Aristada Initio in 2018 and Asimtufii in 2023 created separate regulatory and patent positions.[3,4,6,7,10] Approval dates do not determine patent expiration. The relevant analysis requires review of each product’s Orange Book-listed patents, patent-term adjustments, patent-term extensions, regulatory exclusivity and litigation history.

There is no biosimilar pathway for aripiprazole. Aripiprazole is a small molecule, so competing products use the abbreviated new drug application pathway rather than the abbreviated biologics license application pathway. Long-acting injectable competitors may still face development burdens comparable to complex generics because bioequivalence and drug-release performance can be difficult to demonstrate.

What Paragraph IV challenges and litigation risks affect aripiprazole?

For immediate-release tablets, Paragraph IV risk is commercially mature. The principal question is price, manufacturing scale and channel access rather than whether a generic can be developed.

For long-acting injectables, Paragraph IV exposure is more material. A generic or follow-on applicant could challenge listed patents covering:

• Depot composition.
• Prodrug chemistry.
• Particle size.
• Crystalline form.
• Reconstitution.
• Prefilled syringe presentation.
• Injection interval.
• Initiation dosing.
• Treatment of schizophrenia or bipolar disorder.

A Paragraph IV notice can lead to a 30-month stay of approval for relevant patents under the Hatch-Waxman framework, subject to statutory exceptions and court outcomes.[11] Settlement terms may include licensed entry dates, authorized-generic arrangements, manufacturing restrictions or carve-outs for particular strengths and indications. The commercial effect depends on whether the settlement permits entry before the latest listed patent expiration and whether the entrant can supply enough product to compete.

Because long-acting injectable products are clinically administered, litigation risk extends beyond patent validity. Product liability, sterility, device performance, injection-site reactions and substitution practices can affect launch economics.

What FDA regulatory issues affect aripiprazole excipient commercialization?

The FDA classifies many excipients through the Inactive Ingredient Database, but prior use in one dosage form does not automatically establish suitability for another. An excipient used in an oral tablet may require separate justification for injection, especially where dose, route, concentration or patient population differs.[12]

Key regulatory issues include:

• Novel excipient status.
• Route-specific precedent.
• Maximum daily exposure.
• Impurities and elemental contaminants.
• Nitrosamine or peroxide risk.
• Microbial control.
• Endotoxin limits.
• Extractables and leachables.
• Container closure interaction.
• Preservative effectiveness.
• Particle-size distribution.
• Sterile filtration or aseptic processing.
• Compatibility with autoinjectors and prefilled syringes.

For injectable aripiprazole, excipient suppliers should expect stronger documentation requirements than for oral generics. A supplier with established injectable-grade controls, global regulatory files and low-variability particle or polymer specifications will have a competitive advantage.

How does aripiprazole compare with competing antipsychotic formulations?

Product class	Example	Excipient and manufacturing barrier	Commercial position
Generic oral tablet	Aripiprazole tablets	Low to moderate	High volume, low margin
Orally disintegrating tablet	Aripiprazole ODT	Taste masking and mechanical strength	Niche differentiation
Oral solution	Aripiprazole solution	Solubility, stability and palatability	Pediatric and adherence opportunity
One-month depot	Abilify Maintena	Sterile suspension and reconstitution	Established long-acting market
Two-month depot	Asimtufii	High drug load and extended release	Premium convenience positioning
Prodrug depot	Aristada	Prodrug particle engineering and release control	Strong formulation barrier
Initiation product	Aristada Initio	Rapid exposure plus depot integration	Regimen-specific opportunity

Risperidone, paliperidone and aripiprazole products compete in the long-acting injectable antipsychotic market. Aripiprazole has a commercial advantage for some patients because of its pharmacologic profile, but the product choice is influenced by injection interval, administration logistics, tolerability, insurance coverage and prescriber familiarity.

What generic launch scenarios exist for aripiprazole?

Immediate-release tablet launch

This is the lowest-risk opportunity. Competition centers on:

• Cost of goods.
• API sourcing.
• Manufacturing yield.
• Tablet appearance.
• Wholesaler contracts.
• State substitution rules.
• Supply reliability.

Excipient innovation has limited pricing power unless it produces a meaningful performance difference, such as improved disintegration, lower tablet weight or better stability.

Orally disintegrating tablet launch

An ODT entrant can compete through taste, tablet robustness and package design. The commercial market is smaller than for standard tablets, but institutional and adherence-focused channels can support premium positioning.

Oral solution launch

A solution product can target patients who cannot swallow tablets, caregivers who need flexible dosing and settings where dose titration is important. The principal risks are preservative acceptance, palatability and packaging costs.

Long-acting injectable launch

This is the largest strategic opportunity but requires the greatest capital. A competitor may pursue:

• A conventional aripiprazole monohydrate suspension.
• A differentiated one-month or two-month depot.
• A lower-volume injection.
• A ready-to-use syringe.
• An autoinjector.
• A formulation with reduced reconstitution burden.
• A follow-on to aripiprazole lauroxil.

FDA approval would not guarantee automatic pharmacy substitution for an injectable product. Prescriber adoption, administration-site economics, payer policies and purchasing contracts are central to launch success.

How strong is the aripiprazole patent estate?

The estate is weak for the original oral molecule and materially stronger for long-acting products. Strength comes from formulation complexity rather than from the active ingredient.

Area	Relative patent strength	Reason
Basic oral tablets	Low	Expired compound protection and many substitutable excipients
ODT formulations	Low to moderate	Taste, disintegration and formulation claims may narrow design options
Oral solution	Moderate	Solubility and stability claims can constrain equivalent formulations
Aripiprazole monohydrate depot	Moderate to strong	Particle, suspension, reconstitution and dosing claims
Aripiprazole lauroxil	Stronger	Prodrug, particle engineering, release and regimen claims
Prefilled delivery systems	Moderate	Device and container claims may add protection
Manufacturing processes	Moderate	Process claims can create practical barriers even where composition claims are vulnerable

A robust follow-on strategy should avoid dependence on a single excipient patent. It should use independent control over particle engineering, process conditions, delivery device and clinical dosing evidence.

What licensing and partnership opportunities exist?

The most attractive licensing targets are technologies that improve long-acting delivery without requiring a new active pharmaceutical ingredient. Relevant partners include:

• Injectable-grade excipient manufacturers.
• Particle-engineering companies.
• Depot delivery platform developers.
• Prefilled syringe and autoinjector manufacturers.
• Contract development and manufacturing organizations.
• Companies with psychiatric specialty sales forces.
• Generic manufacturers with sterile injectable capacity.

Licensing value is likely to be highest for a platform that can show lower injection volume, improved stability, reduced preparation time or a longer dosing interval. A commodity excipient license alone is unlikely to command substantial economics unless it is tied to a protected formulation or measurable product advantage.

Key Takeaways

• Immediate-release aripiprazole is a mature generic market with limited excipient-driven pricing power.
• Orally disintegrating tablets remain a practical niche for taste masking, rapid disintegration and adherence-focused products.
• Oral solution opportunities center on sugar reduction, palatability, stability and dosing convenience.
• Long-acting injectable formulations offer the strongest commercial opportunity and the highest technical barrier.
• Aripiprazole monohydrate depots depend on particle control, suspension stability, reconstitution and syringeability.
• Aripiprazole lauroxil products add prodrug particle engineering and release-control barriers.
• There is no biosimilar pathway because aripiprazole is a small molecule.
• Patent risk is concentrated in depot formulations, prodrug technology, dosing regimens, devices and manufacturing processes.
• Injectable-grade excipient quality and sterile manufacturing capacity are strategic assets.
• A commercially credible follow-on product needs a differentiated administration or manufacturing advantage, not only a different filler system.

FAQs

Is aripiprazole suitable for an orally disintegrating tablet?

Yes. Aripiprazole is already marketed in an orally disintegrating format. The main development issues are bitterness, tablet strength, rapid disintegration, moisture control and packaging stability.

Which excipient is most important in long-acting aripiprazole injections?

No single excipient determines performance. Carboxymethylcellulose sodium, mannitol, phosphate components and surfactants can affect suspension stability, tonicity, wetting and injection behavior, but drug particle attributes remain central.

Can a generic company use different excipients in aripiprazole tablets?

Yes, subject to abbreviated new drug application requirements. The alternative formulation must meet quality, bioequivalence and safety standards, and the excipient must be acceptable for the proposed route and exposure.

Is aripiprazole lauroxil a generic version of aripiprazole?

No. Aripiprazole lauroxil is a prodrug with a distinct chemical structure and a long-acting injectable formulation. It is not interchangeable with immediate-release aripiprazole tablets.

What is the best commercial entry point for an excipient supplier?

The strongest entry point is injectable-grade excipient supply tied to a differentiated long-acting formulation, prefilled syringe, autoinjector or lower-volume depot product. Standard tablet fillers face greater price pressure.

References

1. U.S. Food and Drug Administration. (2024). Abilify tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Abilify Discmelt orally disintegrating tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Abilify Maintena: Prescribing information.
4. U.S. Food and Drug Administration. (2024). Asimtufii: Prescribing information.
5. U.S. Food and Drug Administration. (2024). Aripiprazole oral solution: Prescribing information.
6. U.S. Food and Drug Administration. (2015). Aristada: Approval letter and prescribing information.
7. U.S. Food and Drug Administration. (2024). Aristada and Aristada Initio: Prescribing information.
8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
9. U.S. Food and Drug Administration. (2015). FDA approves first generic versions of Abilify.
10. U.S. Food and Drug Administration. (2023). FDA approves two-month formulation of aripiprazole injectable suspension.
11. U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certifications and 30-month stays under the Hatch-Waxman Amendments.
12. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.